{{Rsnum
|rsid=1006798
|Gene=C4orf44
|Chromosome=4
|position=3256646
|Orientation=plus
|GMAF=0.3168
|Gene_s=MSANTD1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 40.0 | 49.2 | 10.8
| HCB | 44.4 | 48.9 | 6.7
| JPT | 36.4 | 59.1 | 4.5
| YRI | 74.6 | 23.8 | 1.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 44.4 | 48.9 | 6.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1006798
|Name_s=
|Gene_s=C4orf44
|Feature=
|Evidence=PubMed ID:19249009
|Annotation=This SNP is part of a haplogroup found to be associated with CAG repeat number expansion in Huntington disease (36 or more CAG repeats) in Europeans and also with intermediate expansion(27-35 repeats) in unaffected individuals(Europeans). This SNP itself was significantly associated(p < 0.0023) with the expansion.
|Drugs=
|Drug Classes=
|Diseases=Huntington Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA164918153
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1006798
|overall_frequency_n=36
|overall_frequency_d=128
|overall_frequency=0.28125
|n_genomes=26
|n_genomes_annotated=0
|n_haplomes=30
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}